Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...

such as ALL (acute lymphocytic leukemia), AML (acute myeloid leukemia), and CML (chronic myeloid leukemia). CLL is the most common leukemia in adults. Most people get diagnosed in their 60s and 70s.

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML ...

conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). In part 1 of this interview, Sekeres discussed the data leading to treosulfan's approval for patients 1 year and ...

However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

Lloret-Madrid P, Boluda B, Martínez-López J, et al. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study. Cancer ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

Among patients with acute myeloid leukemia (AML) in remission following second-line salvage therapy, the immunotherapeutic agent galinpepimut-S (GPS) demonstrated preliminary signals of efficacy and ...